These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 19786360)

  • 21. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme.
    Ruilope LM; Redón J; Schmieder R
    Vasc Health Risk Manag; 2007; 3(1):1-9. PubMed ID: 17583170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on role of direct renin inhibitor in diabetic kidney disease.
    Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V
    Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Remission Clinic approach to halt the progression of kidney disease.
    ;
    J Nephrol; 2011; 24(3):274-81. PubMed ID: 21534237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete inhibition of the renin-angiotensin-aldosterone system; where do we stand?
    Chen SS; Seliger SL; Fried LF
    Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):449-55. PubMed ID: 25014549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).
    Luno J; Praga M; de Vinuesa SG
    Curr Pharm Des; 2005; 11(10):1291-300. PubMed ID: 15853685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
    Björck S; Aurell M
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S59-63. PubMed ID: 16989067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review: renal protection by inhibition of the renin-angiotensin-aldosterone system.
    Berl T
    J Renin Angiotensin Aldosterone Syst; 2009 Mar; 10(1):1-8. PubMed ID: 19286752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point.
    Messerli FH
    J Am Coll Cardiol; 2009 Feb; 53(6):468-70. PubMed ID: 19195602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
    Wolf G; Ritz E
    Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual blockade of the renin-angiotensin system in diabetic nephropathy.
    Cooper M; Boner G
    Diabet Med; 2004 Jan; 21 Suppl 1():15-8. PubMed ID: 15088932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.
    Pisoni R; Faraone R; Ruggenent P; Remuzzi G
    J Nephrol; 2002; 15(4):428-30. PubMed ID: 12243375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of antiproteinuric RAAS blockade: high-dose compared with dual therapy.
    Tobe SW; Dai MO
    Curr Hypertens Rep; 2009 Oct; 11(5):345-53. PubMed ID: 19737451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.